Education
About Us
Working with TipRanks
Follow Us
PROCEPT BioRobotics (PRCT)
NASDAQ:PRCT
PRCT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$37.12 - $103.81
Previous CloseN/A
Volume113.34K
Average Volume (3M)1.38M
Market Cap
$2.31B
Enterprise Value$2.97B
Total Cash (Recent Filing)$316.21M
Total Debt (Recent Filing)$81.81M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Oct 30, 2025EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding55,635,940
10 Day Avg. Volume1,751,750
30 Day Avg. Volume1,376,727
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.28
Enterprise Value/Revenue11.92
Enterprise Value/Gross Profit19.17
Enterprise Value/Ebitda-36.83
Forecast
1Y Price Target
$66.78Price Target Upside60.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Bulls Say, Bears Say
Bulls Say
International ExpansionInternational revenue was $9.6M, a 69% improvement from last year, marking a record revenue performance for the international business.
Leadership ChangeLarry Wood, an industry veteran, is appointed as the new CEO of Procept Biorobotics Corp, bringing valuable perspective and expertise.
Regulatory EnvironmentReimbursement noise is now behind it with solid physician fee and OPPS rates.
Bears Say
Investor SentimentInvestor pushback has been highlighted following recent stock weakness.
Leadership Transition ConcernsThe newly announced CCO transition on top of a CEO transition will create concerns about the business.
Sales GuidanceSystem sales guidance was decreased by 1.5% to account for less replacements than previously expected.
PROCEPT BioRobotics News
PRCT FAQ
What was PROCEPT BioRobotics’s price range in the past 12 months?
PROCEPT BioRobotics lowest stock price was $37.12 and its highest was $103.81 in the past 12 months.
What is PROCEPT BioRobotics’s market cap?
PROCEPT BioRobotics’s market cap is $2.31B.
When is PROCEPT BioRobotics’s upcoming earnings report date?
PROCEPT BioRobotics’s upcoming earnings report date is Oct 30, 2025 which is in 73 days.
How were PROCEPT BioRobotics’s earnings last quarter?
PROCEPT BioRobotics released its earnings results on Aug 06, 2025. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.415 by $0.065.
Is PROCEPT BioRobotics overvalued?
According to Wall Street analysts PROCEPT BioRobotics’s price is currently Undervalued.
Does PROCEPT BioRobotics pay dividends?
PROCEPT BioRobotics does not currently pay dividends.
What is PROCEPT BioRobotics’s EPS estimate?
PROCEPT BioRobotics’s EPS estimate is -0.41.
How many shares outstanding does PROCEPT BioRobotics have?
PROCEPT BioRobotics has 55,635,940 shares outstanding.
What happened to PROCEPT BioRobotics’s price movement after its last earnings report?
PROCEPT BioRobotics reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.415. Following the earnings report the stock price went down -13.351%.
Which hedge fund is a major shareholder of PROCEPT BioRobotics?
Currently, no hedge funds are holding shares in PRCT
PROCEPT BioRobotics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$66.78 (60.57% Upside)
$66.78 (60.57% Upside)
Blogger Sentiment
Bullish
PRCT Sentiment 80%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 464.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $497.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.98%
12-Months-Change
Fundamentals
Return on Equity
-26.40%
Trailing 12-Months
Asset Growth
37.05%
Trailing 12-Months
Company Description
PROCEPT BioRobotics
PROCEPT BioRobotics Corporation (PRCT) is a medical technology company specializing in the development of innovative robotic solutions for the treatment of urological diseases. The company's flagship product, the AquaBeam Robotic System, utilizes advanced imaging and robotics to perform minimally invasive surgery for benign prostatic hyperplasia (BPH), a common condition affecting older men. By focusing on enhancing patient outcomes and reducing the side effects associated with traditional surgical methods, PROCEPT BioRobotics aims to revolutionize the standard of care in the urology sector.
PRCT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call showcased strong revenue growth, increased handpiece sales, improved gross margins, and favorable Medicare updates, indicating positive operational momentum. However, challenges such as the timing of system sales, increased operating expenses, continued net loss, and leadership transitions were highlighted as potential concerns. Despite these challenges, the overall sentiment is positive due to the significant achievements and potential for future growth.View all PRCT earnings summariesPRCT Stock 12 Month Forecast
Average Price Target
$66.78
▲(60.57% Upside)
Technical Analysis
Ownership Overview
2.74% Insiders
36.57% Mutual Funds
26.95% Other Institutional Investors
18.06% Public Companies and
Individual Investors